Retatrutide
Effect Profile
How Retatrutide scores across 8 body systems
26
/ 80 total
Top strengths
Purrptide digest
Tirzepatide hits two hunger buttons. Retatrutide hits three. GLP-1, GIP, and glucagon, all at once — a full keyboard shortcut for your metabolism. Phase 2 trial participants lost 24% of their body weight. That's not a typo, that's a number nobody expected this early. It's still in trials, which means the hype currently outruns the approval. But the early data is loud enough that Eli Lilly is reportedly fast-tracking everything they can.
What this means for you
Not available yet outside trials, but worth watching closely — this could leapfrog everything currently on the market.
Glucagon receptor activation adds an energy-expenditure angle that GLP-1-only drugs don't have. Different mechanism, different patient conversation coming.
Triple agonism is uncharted territory. Nobody fully knows the long-term metabolic tradeoffs of running all three pathways simultaneously.
If Phase 3 confirms Phase 2 numbers, this resets the entire weight-loss drug hierarchy. Eli Lilly knows it.
For the nerds
Triple-Hormone-Receptor Agonist Retatrutide for Obesity
New England Journal of Medicine · DOI: 10.1056/NEJMoa2301972
Read full paper on PubMed →